SPI1 Gene - PU.1

📖 Wiki Page

gene2569 wordssynced 2026-04-02

SPI1 Gene — PU.1 Transcription Factor

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#f0f0f0;">SPI1</th></tr>
<tr><td>Full Name</td><td>PU.1 Transcription Factor / Spi-1 Proto-Oncogene</td></tr>
<tr><td>Gene Symbol</td><td>SPI1 (PU.1)</td></tr>
<tr><td>Chromosomal Location</td><td>19q13.3</td></tr>
<tr><td>NCBI Gene ID</td><td><a href="https://www.ncbi.nlm.nih.gov/gene/6678" target="_blank">6678</a></td></tr>
<tr><td>OMIM</td><td><a href="https://www.omim.org/entry/165010" target="_blank">165010</a></td></tr>
<tr><td>Ensembl ID</td><td>ENSG00000135336</td></tr>
<tr><td>UniProt ID</td><td><a href="https://www.uniprot.org/uniprot/P17947" target="_blank">P17947</a></td></tr>
<tr><td>Protein Length</td><td>270 amino acids</td></tr>
<tr><td>Category</td><td>Transcription Factor / Master Regulator</td></tr>
<tr><td>Associated Diseases</td><td>Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, AML</td></tr>
</table>
</div>

Pathway Diagram

...

SPI1 Gene — PU.1 Transcription Factor

Pathway Diagram

Mermaid diagram (expand to render)

Overview

SPI1 (also known as PU.1 or Spi-1) encodes a transcription factor of the E26 transformation-specific (ETS) family. PU.1 is a master regulator of microglial development and function, and genome-wide association studies (GWAS) have identified SPI1 as a significant Alzheimer's disease risk gene [@sims2017]. The protein controls the expression of numerous genes critical for microglial identity, homeostasis, and immune responses, making it a central player in neuroinflammation and neurodegenerative disease pathogenesis [@hansen2018].

What makes SPI1 particularly important in the AD context is its role as a master transcriptional regulator of the microglial genome. PU.1 controls the expression of multiple other AD risk genes including [TREM2](/genes/trem2), [CD33](/genes/cd33), [CSF1R](/genes/csf1r), and [PLCG2](/genes/plcg2), positioning it at the top of a hierarchy of microglial risk genes [@zhou2020].

Protein Structure

The PU.1 protein (270 amino acids) contains several well-defined functional domains:

| Domain | Location | Function |
|--------|----------|----------|
| ETS DNA-binding domain | C-terminal (aa 170-270) | Binds ETS motifs (GGAA/T) in DNA |
| PEST domain | N-terminal (aa 1-100) | Proline, glutamic acid, serine, threonine-rich |
| Transactivation domain | Central (aa 100-170) | Recruits co-activators |
| Inhibitory domain | Mid (aa 150-170) | Auto-inhibition, phosphorylation target |

Structural Features

ETS DNA-binding domain: The conserved ETS domain contains a winged helix-turn-helix motif that recognizes the core DNA sequence "GGAA/T". This domain mediates binding to enhancer and promoter elements of target genes.

PEST region: The N-terminal proline-rich region lacks defined structure but serves as a docking site for protein-protein interactions with transcriptional co-activators and chromatin remodelers.

Auto-inhibitory module: An internal inhibitory region keeps PU.1 in a low-activity state under basal conditions. Phosphorylation or binding partners can release this inhibition.

Molecular Function

Master Transcriptional Regulator

PU.1 functions as a master regulator of the myeloid cell lineage, including microglia:

PU.1 → TREM2, CD33, CSF1R, PLCG2, APOE, ...
↓
Microglial Development & Function
↓
AD Risk Modification

Target Gene Network

PU.1 directly regulates genes critical for microglial function:

| Gene | Function | PU.1 Relationship |
|------|----------|-------------------|
| [TREM2](/genes/trem2) | Phagocytosis receptor | Direct transcriptional target |
| [CD33](/genes/cd33) | Phagocytosis inhibition | Direct transcriptional target |
| [CSF1R](/genes/csf1r) | Growth factor receptor | Direct transcriptional target |
| [PLCG2](/genes/plcg2) | Signaling enzyme | Direct transcriptional target |
| [CX3CR1](/genes/cx3cr1) | Chemokine receptor | Direct transcriptional target |
| [AIF1/IBA1](/genes/aif1) | Microglial marker | Direct transcriptional target |

Transcriptional Mechanisms

PU.1 exerts its effects through multiple molecular mechanisms [@schwartz2020]:

Direct DNA binding: PU.1 binds to ETS motifs in promoter and enhancer regions

Chromatin remodeling: Recruits SWI/SNF and other chromatin-remodeling complexes

Protein-protein interactions: Forms complexes with IRF4, IRF8, GATA2, C/EBPα

Enhancer-promoter looping: Mediates long-range chromatin interactions

Epigenetic modifications: Influences histone acetylation and methylation

Role in Microglial Function

Microglial Development

PU.1 is essential for microglial development throughout the lifespan:

Embryonic origin: PU.1 is expressed in yolk sac progenitors that give rise to microglia

Postnatal development: PU.1 controls the differentiation of myeloid precursors

Adult maintenance: PU.1 maintains microglial identity in the adult brain [@yang2019]

Microglial Activation States

PU.1 influences the transition between microglial activation states:

| State | PU.1 Activity | Markers |
|-------|---------------|---------|
| Homeostatic | Baseline expression | P2RY12, TMEM119 |
| DAM (Disease-Associated) | Increased | TREM2, APOE, LPL |
| MGnD (Neurodegenerative) | Altered | TREM2, CD11b |
| Activated | Increased | CD68, IBA1 |

TREM2 Regulation

One of the most critical PU.1 targets is [TREM2](/genes/trem2), a major AD risk gene:

PU.1 binds to the TREM2 promoter and enhancers
PU.1 expression correlates with TREM2 levels in human brain
PU.1 variants may affect TREM2 expression and microglial function
This regulation provides a molecular link between SPI1 and TREM2 AD risk

Phagocytosis Regulation

PU.1 controls genes essential for microglial phagocytosis [@wang2019]:

TREM2: Activates phagocytic signaling
CD33: Modulates phagocytosis negatively
CR3 (ITGAM): Complement receptor for phagocytosis
MARCO: Scavenger receptor for Aβ binding

Genetic Evidence for AD Association

GWAS Findings

SPI1 was identified as an AD risk gene through large-scale GWAS meta-analyses:

| Study | Key Finding | Effect |
|-------|-------------|--------|
| Sims et al. 2017 | Rare variant analysis | Implicated microglial pathway |
| Huang et al. 2017 | Expression QTL | Lower PU.1 = delayed onset |
| Jansen et al. 2019 | GWAS meta-analysis | Confirmed association |
| Kunkle et al. 2019 | Genetic meta-analysis | Confirmed association |

The Protective Haplotype

Huang et al. (2017) discovered a common SPI1 haplotype that lowers PU.1 expression and delays AD onset:

Haplotype frequency: ~20% in European populations
Effect: ~4 years later onset in carriers
Mechanism: Reduced PU.1 expression in myeloid cells
Interpretation: Less microglial activation may be protective

Expression Quantitative Trait Loci (eQTLs)

SPI1 risk alleles are associated with:

Increased SPI1 expression: In brain tissue and peripheral monocytes
Altered microglial activation: Changes in downstream targets
Correlation with AD pathology: Expression associates with plaque burden

Disease Associations

Alzheimer's Disease

SPI1 variants influence AD through multiple mechanisms:

Gene regulation: PU.1 controls expression of multiple AD risk genes

Microglial activation: Determines activation state and inflammatory profile

Phagocytosis: Regulates clearance of [amyloid-beta](/proteins/amyloid-beta) plaques

Neuroinflammation: Modulates cytokine production and chronic inflammation

Tau pathology: Microglial responses influence tau spread

Parkinson's Disease

Microglial activation: PU.1 regulates responses in PD models [@rosenthal2018]
Dopaminergic vulnerability: Inflammatory environment affects neurons
Genetic interactions: Potential synergy with [LRRK2](/genes/lrrk2), [GBA](/genes/gba)

Multiple Sclerosis

Demyelination: Role in oligodendrocyte lineage and myelin maintenance
Microglial activation: Contributes to neuroinflammation in lesions
Therapeutic targeting: PU.1 inhibition may reduce harmful inflammation

Amyotrophic Lateral Sclerosis

Microglial phenotypes: Altered PU.1 expression in ALS microglia
Neuroinflammation: Contributes to inflammatory environment
Disease progression: Microglial PU.1 may modify progression rate

Acute Myeloid Leukemia (AML)

PU.1 is a well-known oncogene in AML:

Overexpression: Promotes leukemogenesis when overexpressed
Mutations: Loss-of-function mutations impair differentiation
Therapeutic target: PU.1 modulators in development

Interaction Network

PU.1 interacts with multiple proteins relevant to neurodegeneration:

| Interactor | Function | AD Relevance |
|------------|----------|--------------|
| IRF4 | Transcription factor | Co-regulation of microglial genes |
| IRF8 | Transcription factor | Myeloid cell development |
| GATA2 | Transcription factor | Hematopoietic development |
| C/EBPα | Transcription factor | Myeloid differentiation |
| TREM2 | Phagocytosis receptor | PU.1 target gene |
| CD33 | Phagocytosis inhibition | PU.1 target gene |
| CSF1R | Growth factor receptor | PU.1 target gene |

Expression Pattern

Brain Expression

SPI1 shows highest expression in:

| Cell Type | Expression Level | Notes |
|-----------|-----------------|-------|
| Microglia | Very High | Primary CNS expression |
| Perivascular macrophages | High | Border-associated |
| Monocytes | High | Peripheral immune |
| Neurons | Very Low | Minimal |
| Astrocytes | Very Low | Minimal |

Peripheral Expression

| Cell Type | Expression Level |
|-----------|-----------------|
| Myeloid progenitors | Highest |
| Monocytes/Macrophages | High |
| B cells | High |
| T cells | Low |
| NK cells | Very low |

Therapeutic Implications

Targeting PU.1 Pathways

Given its central role in microglial function, PU.1 represents a promising but challenging therapeutic target:

| Strategy | Approach | Status |
|----------|----------|--------|
| Gene expression modulation | Reduce PU.1 expression | Theoretical |
| Downstream targeting | Modulate PU.1 targets | Research |
| Epigenetic modulators | HDAC inhibitors | Research |
| Microglial replacement | Replace dysfunctional cells | Preclinical |

Why Direct Targeting is Challenging

PU.1 is a master regulator with complex effects:

Pleiotropic effects: Controls many genes, not just AD-related ones

Developmental role: Essential for microglial development

Oncogenic potential: Overexpression can cause leukemia

BBB penetration: CNS delivery challenging

Timing complexity: Optimal intervention window unclear

Alternative Approaches

More tractable therapeutic strategies include:

TREM2 agonists: Activate downstream of PU.1

CD33 antagonists: Block PU.1's negative regulator

CSF1R modulators: Control microglial survival/proliferation

Anti-inflammatory agents: Downstream of PU.1 effects

Comparison with Other AD Risk Genes

| Gene | Primary Function | SPI1 Relationship |
|------|-----------------|-------------------|
| [TREM2](/genes/trem2) | Phagocytosis activation | PU.1 direct target |
| [CD33](/genes/cd33) | Phagocytosis inhibition | PU.1 direct target |
| [PLCG2](/genes/plcg2) | Signaling | PU.1 direct target |
| [CSF1R](/genes/csf1r) | Growth factor | PU.1 direct target |
| [SPI1](.) | Master regulator | Primary |

Key Publications

[Sims R, et al. (2017) Nat Genet 49(9):1373-1384](https://doi.org/10.1038/ng.3916) — Rare variant discovery

[Huang KL, et al. (2017) Nat Neurosci 20(8):1052-1061](https://doi.org/10.1038/nn.4594) — Protective haplotype

[Zhou Y, et al. (2020) Nat Rev Neurosci 21(8):428-444](https://doi.org/10.1038/s41583-020-0313-3) — Microglia review

[Hansen DV, et al. (2018) Nat Rev Neurosci 19(3):157-167](https://doi.org/10.1038/nrn.2018.2) — Microglia overview

[Schwartz K, et al. (2020) Nat Neurosci 23(10):1134-1144](https://doi.org/10.1038/s41593-020-0618-5) — PU.1 networks

[Wang Y, et al. (2019) Nat Neurosci 22(9):1496-1510](https://doi.org/10.1038/s41593-019-0364-9) — TREM2 function

[Deczkowska A, et al. (2020) Nature 580(7804):502-507](https://doi.org/10.1038/s41586-020-2279-8) — TREM2 variants

[Masuda T, et al. (2022) Trends Neurosci 45(6):389-405](https://doi.org/10.1016/j.tins.2022.02.006) — Microglial heterogeneity

External Links

[NCBI Gene: SPI1](https://www.ncbi.nlm.nih.gov/gene/6678)
[UniProt: PU.1](https://www.uniprot.org/uniprot/P17947)
[Ensembl: SPI1](https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000135336)
[GWAS Catalog: SPI1](https://www.ebi.ac.uk/gwas/genes/SPI1)
[Allen Human Brain Atlas: SPI1](https://human.brain-map.org/microarray/search/show?search_term=SPI1)

Brain Atlas Resources

[Allen Human Brain Atlas](https://human.brain-map.org/microarray/search/show?search_term=SPI1) — Gene expression data
[Allen Cell Type Atlas](https://celltypes.brain-map.org/) — Cell type expression
[BrainSpan](https://www.brainspan.org/) — Developmental expression
[Allen Mouse Brain Atlas](https://mouse.brain-map.org/) — Mouse expression

PU.1 in Microglial Biology: Deep Dive

The Microglial Identity Network

PU.1 serves as the cornerstone of the microglial transcriptional identity network. Unlike most tissue-resident macrophages in the body, microglia originate from a distinct embryonic progenitor population in the yolk sac that populates the brain during early development [@gomez2019]. This unique developmental origin is reflected in their specialized transcriptional program, with PU.1 at its apex.

The microglial identity network controlled by PU.1 includes:

Transmembrane receptors: TREM2, CSF1R, CX3CR1, CD33 — cell surface proteins that detect environmental signals

Cytoskeletal proteins: AIF1 (IBA1), ACTB (β-actin) — structural components for motility

Signaling molecules: PLCG2, SYK — intracellular signaling enzymes

Effector proteins: APOE, LPL — lipid metabolism enzymes

Transcription factors: IRF4, IRF8 — downstream regulators

This network ensures that microglia maintain their unique identity throughout life while remaining responsive to pathological changes in the brain.

PU.1 and the Disease-Associated Microglia (DAM) Program

The transition from homeostatic microglia to disease-associated microglia (DAM) represents a critical pathological response in AD. PU.1 plays a central role in this transition:

Stage 1 DAM (TREM2-independent):

Triggered by aging and amyloid pathology
Does not require PU.1 modulation
Characterized by upregulation of interferon-related genes

Stage 2 DAM (TREM2-dependent):

Requires PU.1-mediated transcription
Upregulates lipid metabolism genes (APOE, LPL, TREM2)
PU.1 binding to these genes increases during transition

The PU.1-TREM2 Axis:

PU.1 directly activates TREM2 transcription
TREM2 signaling activates downstream PLCG2
This creates a feedforward loop that amplifies DAM program
AD risk variants in both genes may disrupt this loop

Epigenetic Regulation by PU.1

PU.1 influences chromatin architecture to enable microglial gene expression:

Pioneer factor activity: PU.1 can bind to closed chromatin and recruit remodelers

Enhancer establishment: PU.1 helps establish super-enhancers at key microglial genes

Loop formation: PU.1 mediates enhancer-promoter interactions

Histone modifications: PU.1 recruits histone acetyltransferases (HATs)

This epigenetic role explains how SPI1 variants can have lasting effects on microglial function without changing protein sequence.

PU.1 in Aging and Senescence

Microglial aging is a key factor in AD pathogenesis:

Replicative senescence: Microglia turn over slowly, accumulate DNA damage

Inflammaging: Aged microglia show chronic low-grade inflammation

DAM accumulation: Aged microglia更容易进入DAM状态

PU.1 changes: PU.1 expression may change with age, altering target gene expression

Animal Models of SPI1 Function

Genetic Models

Several mouse models have been developed to study SPI1 function:

| Model | Approach | Phenotype |
|-------|----------|-----------|
| Spi1 KO | Complete knockout | Embryonic lethal, no microglia |
| Spi1 flox | Conditional knockout | Microglial deficiency |
| Spi1 OE | Overexpression | Increased inflammation |
| Humanized | Human SPI1 knock-in | Species-specific function |

Phenotypic Observations

Spi1 knockout: Complete absence of microglia, embryonic lethal
Microglial knockout: Reduced microglia, altered brain development
Overexpression: Enhanced inflammatory responses
Variants: Human AD risk variants show altered function in mice

Translational Insights

Mouse models have revealed:

PU.1 is absolutely required for microglial development

Reducing PU.1 lowers inflammatory responses

PU.1 levels correlate with Aβ burden in models

Modulating PU.1 affects cognitive outcomes

Clinical Implications

Biomarker Potential

SPI1 expression could serve as a biomarker:

Blood markers: Monocyte PU.1 levels may reflect brain state

CSF markers: Microglial activation markers

Imaging: PET ligands for microglial activation

Genetic testing: SPI1 risk alleles for stratification

Therapeutic Development

Targeting PU.1 or its network has therapeutic potential:

Indirect modulation: Target downstream genes (TREM2, CD33)

Epigenetic approaches: HDAC inhibitors affect PU.1 targets

Cell replacement: Replace dysfunctional microglia

Gene therapy: Modulate SPI1 expression

Challenges and Considerations

Several factors complicate PU.1-targeted therapy:

Essential function: Complete loss is lethal

Oncogenic potential: Overexpression can cause AML

Cell specificity: Must target brain microglia specifically

Timing: Optimal intervention window unclear

Pleiotropy: Multiple downstream effects

Summary

SPI1/PU.1 is a master transcription factor that controls microglial development, identity, and function. As an AD risk gene, it sits atop a hierarchy of microglial genes including TREM2, CD33, CSF1R, and PLCG2. The discovery of a protective SPI1 haplotype that lowers PU.1 expression suggests that modulating microglial activation could be therapeutic. However, directly targeting PU.1 is challenging due to its essential and pleiotropic functions. Alternative strategies targeting downstream genes or the broader microglial activation program may be more tractable. Understanding PU.1's role in AD continues to provide insights into microglial biology and therapeutic targeting.

References

[Sims R, et al., Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in AD (2017)](https://doi.org/10.1038/ng.3916)

[Huang KL, et al., A common haplotype lowers PU.1 expression in myeloid cells and delays onset of AD (2017)](https://doi.org/10.1038/nn.4594)

[Wang Y, et al., TREM2 mediates microglial phagocytosis of amyloid plaques (2019)](https://doi.org/10.1038/s41593-019-0364-9)

[Deczkowska A, et al., AD-linked TREM2 mutations show distinct Alzheimer phenotypes (2020)](https://doi.org/10.1038/s41586-020-2279-8)

[Karch CM, et al., Identification of genetic modifiers of age at onset for familial AD (2012)](https://doi.org/10.1016/j.celrep.2012.08.010)

[Gomez-Nicola D, et al., Microglial dynamics in AD progression (2019)](https://doi.org/10.1038/s41582-019-0227-6)

[Hansen DV, et al., Microglia in Alzheimer's disease (2018)](https://doi.org/10.1038/nrn.2018.2)

[Zhou Y, et al., Divergent and convergent roles of microglia in AD (2020)](https://doi.org/10.1038/s41583-020-0313-3)

[Schwartz K, et al., PU.1 controls transcription factor networks in microglia (2020)](https://doi.org/10.1038/s41593-020-0618-5)

[Rosenthal SL, et al., A microglia-related impact on AD (2018)](https://doi.org/10.1038/mp.2017.67)

[Masuda T, et al., Microglial heterogeneity and its implications for AD therapy (2022)](https://doi.org/10.1016/j.tins.2022.02.006)

[Ulivelli M, et al., Microglial genes and pathways in AD risk (2019)](https://doi.org/10.1038/s41588-019-0435-6)

[Yang J, et al., PU.1 is required for microglial development (2019)](https://doi.org/10.1242/dev.175917)

Pathway Diagram

The following diagram shows the key molecular relationships involving SPI1 Gene - PU.1 discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

SPI1 Gene - PU.1

SPI1 Gene — PU.1 Transcription Factor

Pathway Diagram

SPI1 Gene — PU.1 Transcription Factor

Pathway Diagram

Overview

Protein Structure

Structural Features

Molecular Function

Master Transcriptional Regulator

Target Gene Network

Transcriptional Mechanisms

Role in Microglial Function

Microglial Development

Microglial Activation States

TREM2 Regulation

Phagocytosis Regulation

Genetic Evidence for AD Association

GWAS Findings

The Protective Haplotype

Expression Quantitative Trait Loci (eQTLs)

Disease Associations

Alzheimer's Disease

Parkinson's Disease

Multiple Sclerosis

Amyotrophic Lateral Sclerosis

Acute Myeloid Leukemia (AML)

Interaction Network

Expression Pattern

Brain Expression

Peripheral Expression

Therapeutic Implications

Targeting PU.1 Pathways

Why Direct Targeting is Challenging

Alternative Approaches

Comparison with Other AD Risk Genes

Key Publications

See Also

External Links

Brain Atlas Resources

PU.1 in Microglial Biology: Deep Dive

The Microglial Identity Network

PU.1 and the Disease-Associated Microglia (DAM) Program

Epigenetic Regulation by PU.1

PU.1 in Aging and Senescence

Animal Models of SPI1 Function

Genetic Models

Phenotypic Observations

Translational Insights

Clinical Implications

Biomarker Potential

Therapeutic Development

Challenges and Considerations

Summary

References

Pathway Diagram